The balance sheet exhibits structural vulnerability, with goodwill accounting for $10.7M of the $27.4M total asset base as of 2025Q4, while retained earnings have eroded to -$141.2M.
TuHURA Biosciences, Inc. (HURA) balance sheet — 12-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 |
|---|
| Total Current Assets | 1.66M | 4.62M | 19.61M | 4.16M | 14.74M | 5.68M | 11.79M | 2.76M | 4.03M | 7.05M | 7.87M | 6.32M | 2.03M |
| Cash & Short-Term Investments | 995.98K | 3.62M | 12.66M | 3.67M | 14.25M | 5.55M | 10.54M | 2.39M | 3.72M | 5.97M | 6.59M | 6.16M | 1.75M |
| Cash Only | 995.98K | 3.62M | 12.66M | 3.67M | 14.25M | 5.55M | 10.54M | 2.39M | 3.72M | 5.97M | 6.59M | 6.16M | 1.75M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 222.7K | 334.44K | 101.42K | 0 | 0 | 0 | 26.19K | 39.52K | 76.59K | 18.39K | 25.83K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 214.7K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 659.89K | 1M | 316.35K | 159.33K | 390.35K | 135.13K | 1.26M | 365K | 280.25K | 1.03M | 1.21M | 0 | 0 |
| Total Non-Current Assets | 30.09M | 22.73M | 356.3K | 202.99K | 452.32K | 721.04K | 1.75M | 181K | 12.06K | 28.41K | 40.29K | 36.02K | 550.12K |
| Property, Plant & Equipment | 745.67K | 685.17K | 322.53K | 202.99K | 418.55K | 617.14K | 150K | 2K | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 10.74M | 10.74M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.06K | 28.41K | 40.29K | 36.02K | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 18.61M | 11.31M | 33.77K | 0 | 33.77K | 103.9K | 1.6M | 179K | 0 | 0 | 0 | 0 | 550.12K |
| Total Assets | 31.75M | 27.35M | 19.97M | 4.36M | 15.2M | 6.4M | 13.54M | 2.94M | 4.04M | 7.07M | 7.91M | 6.36M | 2.58M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 652.31% | 36.99% | 357.76% | -71.3% | 137.36% | -52.73% | 360.96% | -27.23% | -42.94% | -10.57% | 24.47% | 146.79% | - |
| Total Current Liabilities | 9.26M | 5.92M | 5.33M | 3.6M | 2.87M | 7.15M | 2.78M | 2.67M | 2.07M | 1.64M | 1.3M | 627.45K | 853.09K |
| Accounts Payable | 3.08M | 3.77M | 3.15M | 1.87M | 1.92M | 413.79K | 2.22M | 2.01M | 1.74M | 1.48M | 1.27M | 627.45K | 0 |
| Days Payables Outstanding | 58.04K | - | - | 12.39K | 11.65K | 2.52K | 25.31K | 73.4K | 38.95K | 22K | 27.81K | 22.26K | - |
| Short-Term Debt | 214.18K | 197.35K | 0 | 0 | 0 | 644.07K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.96M | 1.53M | 1.16M | 137K | 675K | 456K | 561K | 664K | 325.21K | 160.43K | 33.09K | 0 | 853.09K |
| Current Ratio | 0.18x | 0.78x | 3.68x | 1.16x | 5.13x | 0.79x | 4.24x | 1.03x | 1.94x | 4.30x | 6.03x | 10.07x | 2.37x |
| Quick Ratio | 0.18x | 0.78x | 3.64x | 1.16x | 5.13x | 0.79x | 4.24x | 1.03x | 1.94x | 4.30x | 6.03x | 10.07x | 2.37x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 3.99M | 501.55K | 42.7K | 2.32M | 20.74K | 0 | 182K | 0 | 0 | 1.12K | 28.14K | 869.58K | 2.54M |
| Long-Term Debt | 192.85K | 303.63K | 0 | 2.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 250.07K | 0 | 42.7K | 0 | 20.74K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 593.76K | 197.92K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.6M | 0 | 0 | 0 | 0 | 0 | 182K | 0 | 0 | 1.12K | 28.14K | 869.58K | 2.54M |
| Total Liabilities | 13.25M | 6.42M | 5.37M | 5.92M | 2.89M | 7.15M | 2.96M | 2.67M | 2.07M | 1.64M | 1.33M | 1.5M | 3.4M |
| Total Debt | 407.02K | 700.02K | 202.54K | 2.34M | 138.22K | 644.07K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -588.95K | -2.92M | -12.45M | -1.32M | -14.11M | -4.9M | -10.54M | -2.39M | -3.72M | -5.97M | -6.59M | -6.16M | -1.75M |
| Debt / Equity | 0.02x | 0.03x | 0.01x | - | 0.01x | - | - | - | - | - | - | - | - |
| Debt / EBITDA | -0.01x | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.02x | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -26.32x | -47.06x | -4.24x | -445.21x | - | -35.01x | -318.15x | - | - | - | - | - | -2078.28x |
| Total Equity | 18.5M | 20.93M | 14.59M | -1.56M | 12.3M | -747.82K | 10.58M | 263K | 1.97M | 5.44M | 6.58M | 4.86M | -821.49K |
| Equity Growth % | 1063.68% | 43.43% | 1036.26% | -112.67% | 1745.31% | -107.07% | 3923.19% | -86.63% | -63.8% | -17.38% | 35.39% | 691.46% | - |
| Book Value per Share | 0.29 | 0.44 | 0.78 | -2.07 | 265.83 | -26.87 | 715.37 | 44.07 | 1337.55 | 4559.75 | 9556.19 | 7766.25 | -1510.59 |
| Total Shareholders' Equity | 18.5M | 20.93M | 14.59M | -1.56M | 12.3M | -747.82K | 10.58M | 263K | 1.97M | 5.44M | 6.58M | 4.86M | -821.49K |
| Common Stock | 63.68K | 59.34K | 42.32K | 6.8K | 4.53K | 4.53K | 33K | 11K | 3.84K | 22.97K | 14.51K | 11.19K | 39.46K |
| Retained Earnings | -157.95M | -141.18M | -111.12M | -88.47M | -59.16M | -49.48M | -111.22M | -69.72M | -60.58M | -52.44M | -41.12M | -32.24M | -18.61M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 21K | 21K | 6.61M | 8.25M | 4.59M | 1.68M | 110.61K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying HURA stock.
As of 2025, TuHURA Biosciences, Inc. (HURA) had total assets of $27.4M including $4.6M in current assets.
TuHURA Biosciences, Inc. (HURA) carries total debt of $0.7M, offset by $3.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
TuHURA Biosciences, Inc. (HURA) has total shareholders' equity (book value) of $20.9M ($0.44 book value per share). Book value represents the net worth of the company belonging to common stock holders.
TuHURA Biosciences, Inc. (HURA) reported a current ratio of 0.78x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Imminent liquidity exhaustion
Metrics are mathematically derived from official filings.
Critical Cash Runway Depletion Risk
As reported in recent financial filings, TuHURA's cash and equivalents plummeted to $3.6M by 2025Q4, resulting in a current ratio of 0.78, which suggests the company lacks the necessary liquidity buffer to sustain its ongoing Phase 3 clinical trial commitments without immediate external capital intervention.
The rapid decline in the current ratio from 3.68 in 2024Q4 to 0.78 in 2025Q4 highlights a deteriorating ability to cover short-term obligations. This liquidity profile indicates that the firm is likely operating on a month-to-month basis, leaving little room for operational delays or unforeseen clinical trial expenses.
Goodwill Concentration and Asset Quality
Based on the company's reported figures, goodwill accounts for $10.7M of the $27.4M total asset base as of 2025Q4, indicating that a significant portion of the balance sheet is tied to intangible merger-related valuations rather than tangible assets capable of supporting near-term clinical operations.
The reliance on goodwill following the Kintara merger suggests that the asset base is highly sensitive to impairment risks if the underlying clinical programs fail to meet regulatory milestones. Investors should monitor whether these intangible assets remain recoverable as the company continues to burn through its limited cash reserves.
Equity Erosion and Dilution Pressure
According to the latest balance sheet data, TuHURA's equity position has been characterized by extreme volatility, with retained earnings reaching -$141.2M in 2025Q4, a trend that underscores the persistent erosion of shareholder value typical of a pre-revenue entity heavily reliant on dilutive financing to fund development.
The negative trajectory of retained earnings reflects the cumulative impact of R&D-heavy spending without offsetting revenue generation. Given the current capital structure, it appears highly probable that management will need to pursue further equity offerings, which would likely result in significant dilution for existing shareholders.
Hidden Liabilities and Structural Fragility
As disclosed in financial statements, the company's balance sheet is distorted by merger-related accounting and contingent liabilities, which, when combined with a cash balance of only $3.6M, suggests that the headline equity figure may significantly overstate the firm's actual financial flexibility and long-term operational viability.
The presence of legacy obligations from the Kintara merger complicates the assessment of the company's true net worth. Analysts should be wary that the reported equity may not accurately reflect the capital required to reach commercialization, as the firm remains vulnerable to further balance sheet restructuring.